샘플 요청 목록

 카트 문의
시장보고서
상품코드
1793640

세계의 신경질환 진단 시장

Neurological Disorder Diagnostics
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 367 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 신경질환 진단 시장은 2030년까지 136억 달러에 이를 전망

2024년에 99억 달러로 추정되는 신경질환 진단 세계 시장은 2024-2030년간 CAGR 5.6%로 성장하여 2030년에는 136억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 영상 진단은 CAGR 4.6%를 나타내고, 분석 기간 종료시에는 86억 달러에 이를 것으로 예측됩니다. In-Vitro Diagnostics 분야의 성장률은 분석 기간중 CAGR 7.3%로 추정됩니다.

미국 시장은 27억 달러, 중국은 CAGR 8.6%를 보일 것으로 예측

미국의 신경질환 진단 시장은 2024년에 27억 달러로 추정됩니다. 세계 2위 경제대국인 중국은 분석 기간인 2024-2030년 CAGR 8.6%로 성장을 지속하여 2030년까지 27억 달러 규모에 이를 것으로 예측됩니다. 기타 주목해야 할 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 2.8%와 5.4%를 보일 것으로 예측됩니다. 유럽에서는 독일이 CAGR 3.6%를 나타낼 전망입니다.

세계의 신경질환 진단 시장 - 주요 동향과 촉진요인 정리

복잡해지는 질병은 진단 접근법을 어떻게 변화시키고 있는가?

신경질환에는 알츠하이머병, 파킨슨병, 다발성 경화증, 간질, 뇌졸중 등 다양한 질환이 포함됩니다. 이들 질환은 중복된 증상을 보이는 경우가 많아 정확한 진단이 점점 더 복잡해지고 있습니다. 신경퇴행에 대한 이해도가 높아짐에 따라, 진단 방법은 초기 단계의 식별과 개별화 평가로 전환되고 있습니다. CT 스캔이나 MRI와 같은 전통적인 진단 도구는 현재 PET 영상, 뇌척수액 분석, 뇌척수액 분석, 전기생리학적 모니터링과 같은 첨단 기술로 보완되고 있습니다.

분자진단법, 특히 아밀로이드반과 타우 단백질을 검출하는 바이오마커를 이용한 진단법은 임상 증상이 나타나기 훨씬 전에 신경퇴행성 질환을 확인하는 데 있어 그 중요성이 커지고 있습니다. 보다 빠르고 정확한 검출을 위한 이러한 움직임은 단백질체학, 유전체학, 유전체학, 이미지 인포매틱스의 발전으로 뒷받침되고 있습니다. 또한, 디지털 플랫폼과 AI 기반 분석을 통합함으로써 임상의는 증상이 모호하거나 시간이 지남에 따라 변화하는 경우에도 서로 다른 신경 질환을 보다 효율적으로 구분할 수 있게 되었습니다.

진단 정확도 향상에 있어 기술의 역할은 무엇인가?

기술의 통합으로 신경학적 진단의 정확도와 범위가 크게 향상되었습니다. 고해상도 영상 진단 도구를 통해 뇌의 형태, 혈관 이상, 기능 장애에 대한 자세한 통찰력을 얻을 수 있게 되었습니다. 확산텐서영상이나 기능적 MRI와 같은 MRI 기술은 특히 간질이나 외상성 뇌손상 평가에서 뇌 활동을 매핑하는 데 점점 더 많이 사용되고 있습니다. 한편, 뇌파 및 MEG 기술은 간질, 수면장애, 뇌질환의 실시간 신경전기 모니터링에 필수적입니다.

또 다른 중요한 트렌드는 외래나 재택에서 편리하게 사용할 수 있는 비침습적이고 휴대 가능한 진단 장비의 등장입니다. 웨어러블 신경 모니터링 시스템 및 모바일 뇌파 솔루션은 뇌 활동을 지속적으로 추적하는 데 도움이 되며, 의사는 표준 임상 검사에서 나타나지 않는 간헐적인 이상 징후를 파악할 수 있습니다. 클라우드 연결과 원격 진단을 통해 특히 서비스 소외 지역과 농촌 지역에서 전문적인 평가에 대한 접근성이 더욱 확대되고 있습니다.

개인 맞춤형 진단이 임상적 우선순위가 되고 있는 이유는 무엇일까?

개인 맞춤형 의료가 강조되면서 신경학적 진단의 해석과 적용 방법이 달라지고 있습니다. 신경질환의 진행과 치료에 대한 반응에 현저한 불균일성을 보임에 따라, 진단법은 개인의 위험 프로파일에 맞게 조정되고 있습니다. 여기에는 유전성 신경퇴행성 질환(헌팅턴병, 가족성 알츠하이머병 등)을 검출하기 위한 유전자 스크리닝, 인지기능 검사 패턴과 영상 데이터를 기반으로 질환의 경과를 평가하기 위한 머신러닝 알고리즘 활용이 포함됩니다.

뇌 스캔, 신경심리학적 평가, 체액 바이오마커, 유전자 검사 등의 데이터를 결합한 멀티모달 진단은 임상시험 및 연구 프로그램에 도입이 활발히 진행되고 있습니다. 이러한 접근법은 질병의 조기 발견에 도움이 될 뿐만 아니라 더 나은 치료법 선택, 반응 모니터링, 예후 예측에 도움을 줄 수 있습니다. 제약사들도 진단약 개발 기업들과 협력하여 신경학에 특화된 의약품 개발 프로그램에 동반진단약을 포함시키고자 노력하고 있습니다.

신경질환 진단 시장의 성장은 몇 가지 요인에 의해 이루어집니다.

인구 고령화와 생활습관 관련 위험요인 증가로 인해 전 세계적으로 신경퇴행성 질환 및 신경혈관질환의 부담이 증가함에 따라 정확한 조기 진단에 대한 요구가 높아지고 있습니다. 영상 기술, 바이오마커 탐색, 디지털 진단 플랫폼의 발전으로 평가의 신뢰성과 접근성이 높아지고 있습니다. AI와 데이터 분석을 신경 진단 시스템에 통합하여 특히 복잡한 사례에서 진단 정확도를 더욱 향상시키고 있습니다. 신경과학 연구에 대한 투자 증가와 전문 진단센터의 가용성 확대도 시장 확대를 뒷받침하고 있습니다. 재택 신경학 평가 도구의 개발은 조기 개입 전략에 대한 규제 당국의 지원과 함께 헬스케어 시스템 전반에서 진단 제품 개발의 기술 혁신을 지속적으로 촉진하고 있습니다.

부문

제품(영상진단, 체외진단);질환(유전성 신경질환, 면역성 신경질환, 종양수반성 증후군, 종양 수반성 신경장애);최종사용자(병원 및 전문 클리닉, 진단센터, 외래수술센터(ASC) 최종사용자)

조사 대상 기업 예

  • Abbott Laboratories
  • Advanced Brain Monitoring, Inc.
  • Biogen Inc.
  • Bio-Rad Laboratories, Inc.
  • Canon Medical Systems Corporation
  • Elekta AB
  • F. Hoffmann-La Roche Ltd
  • Fujifilm Holdings Corporation
  • GE HealthCare
  • Hologic, Inc.
  • IXICO plc
  • Lifelines Neuro Company LLC
  • Masimo Corporation
  • Medtronic plc
  • NeuroPace, Inc.
  • Natus Medical Incorporated
  • Nihon Kohden Corporation
  • Philips Healthcare(Koninklijke Philips)
  • QIAGEN N.V.
  • Siemens Healthineers AG

AI 통합

당사는 유효한 전문가 컨텐츠와 AI툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 LLM나 업계 고유 SLM를 조회하는 일반적인 규범에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 큐레이트된 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수익원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

LSH 25.08.26

Global Neurological Disorder Diagnostics Market to Reach US$13.6 Billion by 2030

The global market for Neurological Disorder Diagnostics estimated at US$9.9 Billion in the year 2024, is expected to reach US$13.6 Billion by 2030, growing at a CAGR of 5.6% over the analysis period 2024-2030. Imaging Diagnostics, one of the segments analyzed in the report, is expected to record a 4.6% CAGR and reach US$8.6 Billion by the end of the analysis period. Growth in the In-Vitro Diagnostics segment is estimated at 7.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.7 Billion While China is Forecast to Grow at 8.6% CAGR

The Neurological Disorder Diagnostics market in the U.S. is estimated at US$2.7 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.7 Billion by the year 2030 trailing a CAGR of 8.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.8% and 5.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.6% CAGR.

Global Neurological Disorder Diagnostics Market - Key Trends & Drivers Summarized

How Is Evolving Disease Complexity Reshaping Diagnostic Approaches?

Neurological disorders encompass a wide range of conditions such as Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, epilepsy, and stroke. These disorders often present with overlapping symptoms, making accurate diagnosis increasingly complex. As the understanding of neurodegeneration advances, diagnostics are shifting toward early-stage identification and personalized evaluation. Traditional diagnostic tools like CT scans and MRIs are now being complemented by advanced techniques including PET imaging, cerebrospinal fluid analysis, and electrophysiological monitoring.

Molecular diagnostics, particularly those using biomarkers for detecting amyloid plaques or tau proteins, are gaining importance in identifying neurodegenerative conditions well before the onset of clinical symptoms. This push for earlier and more precise detection has been supported by advances in proteomics, genomics, and imaging informatics. Integration of digital platforms and AI-based analytics is also enabling clinicians to distinguish between different neurological conditions more efficiently, even when symptoms are ambiguous or evolve over time.

What Role Does Technology Play in Expanding Diagnostic Accuracy?

Technological integration has significantly enhanced the accuracy and scope of neurological diagnostics. High-resolution imaging tools now provide detailed insights into brain morphology, vascular anomalies, and functional disturbances. MRI techniques like diffusion tensor imaging and functional MRI are increasingly used for mapping brain activity, particularly in epilepsy and traumatic brain injury assessments. Meanwhile, EEG and MEG technologies continue to be vital for real-time neuroelectrical monitoring in epilepsy, sleep disorders, and encephalopathies.

Another key trend is the rise of non-invasive and portable diagnostic devices, which offer convenience in outpatient or home-based settings. Wearable neuro-monitoring systems and mobile EEG solutions are helping track brain activity continuously, allowing physicians to identify intermittent abnormalities that may not appear during standard clinical tests. Cloud connectivity and remote diagnostics are further widening access to specialized evaluations, particularly in underserved or rural areas.

Why Are Personalized Diagnostics Becoming a Clinical Priority?

Growing emphasis on personalized medicine is transforming how neurological diagnostics are interpreted and applied. With neurological disorders showing significant heterogeneity in progression and response to treatment, diagnostics are now being tailored to individual risk profiles. This includes using genetic screening to detect hereditary neurodegenerative disorders, such as Huntington’s disease or familial Alzheimer’s, as well as leveraging machine learning algorithms to assess disease trajectory based on cognitive test patterns and imaging data.

Multimodal diagnostics, which combine data from brain scans, neuropsychological assessments, fluid biomarkers, and genetic tests, are being increasingly deployed in clinical trials and research programs. These approaches not only help in early disease detection but also support better treatment selection, response monitoring, and prognosis prediction. Pharmaceutical companies are also collaborating with diagnostics developers to embed companion diagnostics into neurology-focused drug development programs.

Growth in the neurological disorder diagnostics market is driven by several factors.

Increasing global burden of neurodegenerative and neurovascular disorders, driven by aging populations and rising lifestyle-related risk factors, has created strong demand for accurate and early-stage diagnostics. Advancements in imaging technology, biomarker discovery, and digital diagnostic platforms have made evaluations more reliable and accessible. Integration of AI and data analytics into neurodiagnostic systems is further improving diagnostic precision, especially in complex cases. Rising investment in neuroscience research and the growing availability of specialized diagnostic centers are also supporting market expansion. Adoption of home-based neurological assessment tools, along with regulatory support for early intervention strategies, continues to encourage innovation in diagnostic product development across healthcare systems.

SCOPE OF STUDY:

The report analyzes the Neurological Disorder Diagnostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Imaging Diagnostics, In-Vitro Diagnostics); Disorder (Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder, Paraproteinemic Neuropathies Disorder); End-Use (Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use, Ambulatory Surgery Centers End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • Abbott Laboratories
  • Advanced Brain Monitoring, Inc.
  • Biogen Inc.
  • Bio-Rad Laboratories, Inc.
  • Canon Medical Systems Corporation
  • Elekta AB
  • F. Hoffmann-La Roche Ltd
  • Fujifilm Holdings Corporation
  • GE HealthCare
  • Hologic, Inc.
  • IXICO plc
  • Lifelines Neuro Company LLC
  • Masimo Corporation
  • Medtronic plc
  • NeuroPace, Inc.
  • Natus Medical Incorporated
  • Nihon Kohden Corporation
  • Philips Healthcare (Koninklijke Philips)
  • QIAGEN N.V.
  • Siemens Healthineers AG

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Neurological Disorder Diagnostics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Incidence of Neurological Disorders Drives Demand for Early Diagnostic Solutions
    • Advancements in Neuroimaging Technologies Spur Growth in Accurate and Non-Invasive Diagnostics
    • Increased Adoption of AI and Machine Learning Enhances Diagnostic Accuracy and Workflow Efficiency
    • Expansion of Point-of-Care Neurological Testing Devices Strengthens Market Accessibility
    • Integration of Genomic and Molecular Biomarkers Propels Personalized Neurology Diagnostics
    • Aging Population and Age-Associated Cognitive Decline Expand Addressable Market Opportunity
    • Growing Focus on Pre-Symptomatic Detection Generates Demand for Predictive Neurological Tools
    • Widening Application of EEG and MEG Systems Drives Clinical Adoption Across Hospitals and Clinics
    • Rise in Concussions and Sports-Related Brain Injuries Throws the Spotlight on Portable Diagnostic Tools
    • Increased Use of Companion Diagnostics in Neurology Strengthens Business Case for Targeted Testing
    • Digital Neurology Platforms and Remote Monitoring Tools Create New Diagnostic Pathways
    • Widespread Use of Wearables in Cognitive Health Monitoring Drives Market Penetration
    • Emerging Role of Liquid Biopsy in CNS Disorders Expands Future Diagnostic Capabilities
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Neurological Disorder Diagnostics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Neurological Disorder Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Neurological Disorder Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Imaging Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Imaging Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Imaging Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for In-Vitro Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for In-Vitro Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for In-Vitro Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Genetic Neurological Disorder by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Genetic Neurological Disorder by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Genetic Neurological Disorder by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Immunological Neurological Disorder by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Immunological Neurological Disorder by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Immunological Neurological Disorder by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Paraneoplastic Syndrome Disorder by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Paraneoplastic Syndrome Disorder by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Paraneoplastic Syndrome Disorder by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Paraproteinemic Neuropathies Disorder by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Paraproteinemic Neuropathies Disorder by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Paraproteinemic Neuropathies Disorder by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Hospitals & Specialty Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Hospitals & Specialty Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Hospitals & Specialty Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Diagnostic Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Diagnostic Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Diagnostic Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for Ambulatory Surgery Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Neurological Disorder Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Neurological Disorder Diagnostics by Product - Percentage Breakdown of Value Sales for Imaging Diagnostics and In-Vitro Diagnostics for the Years 2014, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Neurological Disorder Diagnostics by Disorder - Percentage Breakdown of Value Sales for Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder for the Years 2014, 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Neurological Disorder Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for Neurological Disorder Diagnostics by Product - Percentage Breakdown of Value Sales for Imaging Diagnostics and In-Vitro Diagnostics for the Years 2014, 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Neurological Disorder Diagnostics by Disorder - Percentage Breakdown of Value Sales for Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder for the Years 2014, 2025 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Neurological Disorder Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • JAPAN
    • Neurological Disorder Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Japan 16-Year Perspective for Neurological Disorder Diagnostics by Product - Percentage Breakdown of Value Sales for Imaging Diagnostics and In-Vitro Diagnostics for the Years 2014, 2025 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for Neurological Disorder Diagnostics by Disorder - Percentage Breakdown of Value Sales for Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder for the Years 2014, 2025 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Neurological Disorder Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • CHINA
    • Neurological Disorder Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 59: China Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: China 16-Year Perspective for Neurological Disorder Diagnostics by Product - Percentage Breakdown of Value Sales for Imaging Diagnostics and In-Vitro Diagnostics for the Years 2014, 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: China 16-Year Perspective for Neurological Disorder Diagnostics by Disorder - Percentage Breakdown of Value Sales for Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder for the Years 2014, 2025 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: China 16-Year Perspective for Neurological Disorder Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • EUROPE
    • Neurological Disorder Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Neurological Disorder Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Europe 16-Year Perspective for Neurological Disorder Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Europe 16-Year Perspective for Neurological Disorder Diagnostics by Product - Percentage Breakdown of Value Sales for Imaging Diagnostics and In-Vitro Diagnostics for the Years 2014, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Neurological Disorder Diagnostics by Disorder - Percentage Breakdown of Value Sales for Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder for the Years 2014, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Neurological Disorder Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • FRANCE
    • Neurological Disorder Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 80: France Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: France 16-Year Perspective for Neurological Disorder Diagnostics by Product - Percentage Breakdown of Value Sales for Imaging Diagnostics and In-Vitro Diagnostics for the Years 2014, 2025 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: France 16-Year Perspective for Neurological Disorder Diagnostics by Disorder - Percentage Breakdown of Value Sales for Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder for the Years 2014, 2025 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: France 16-Year Perspective for Neurological Disorder Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • GERMANY
    • Neurological Disorder Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Germany 16-Year Perspective for Neurological Disorder Diagnostics by Product - Percentage Breakdown of Value Sales for Imaging Diagnostics and In-Vitro Diagnostics for the Years 2014, 2025 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Germany 16-Year Perspective for Neurological Disorder Diagnostics by Disorder - Percentage Breakdown of Value Sales for Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder for the Years 2014, 2025 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Germany 16-Year Perspective for Neurological Disorder Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Italy 16-Year Perspective for Neurological Disorder Diagnostics by Product - Percentage Breakdown of Value Sales for Imaging Diagnostics and In-Vitro Diagnostics for the Years 2014, 2025 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Italy 16-Year Perspective for Neurological Disorder Diagnostics by Disorder - Percentage Breakdown of Value Sales for Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder for the Years 2014, 2025 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Italy 16-Year Perspective for Neurological Disorder Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Neurological Disorder Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 107: UK Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: UK 16-Year Perspective for Neurological Disorder Diagnostics by Product - Percentage Breakdown of Value Sales for Imaging Diagnostics and In-Vitro Diagnostics for the Years 2014, 2025 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: UK 16-Year Perspective for Neurological Disorder Diagnostics by Disorder - Percentage Breakdown of Value Sales for Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder for the Years 2014, 2025 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: UK 16-Year Perspective for Neurological Disorder Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 116: Spain Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Spain Historic Review for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: Spain 16-Year Perspective for Neurological Disorder Diagnostics by Product - Percentage Breakdown of Value Sales for Imaging Diagnostics and In-Vitro Diagnostics for the Years 2014, 2025 & 2030
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: Spain 16-Year Perspective for Neurological Disorder Diagnostics by Disorder - Percentage Breakdown of Value Sales for Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder for the Years 2014, 2025 & 2030
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: Spain 16-Year Perspective for Neurological Disorder Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 125: Russia Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Russia Historic Review for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: Russia 16-Year Perspective for Neurological Disorder Diagnostics by Product - Percentage Breakdown of Value Sales for Imaging Diagnostics and In-Vitro Diagnostics for the Years 2014, 2025 & 2030
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: Russia 16-Year Perspective for Neurological Disorder Diagnostics by Disorder - Percentage Breakdown of Value Sales for Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder for the Years 2014, 2025 & 2030
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Russia 16-Year Perspective for Neurological Disorder Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Rest of Europe 16-Year Perspective for Neurological Disorder Diagnostics by Product - Percentage Breakdown of Value Sales for Imaging Diagnostics and In-Vitro Diagnostics for the Years 2014, 2025 & 2030
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Rest of Europe 16-Year Perspective for Neurological Disorder Diagnostics by Disorder - Percentage Breakdown of Value Sales for Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder for the Years 2014, 2025 & 2030
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 16-Year Perspective for Neurological Disorder Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Neurological Disorder Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Neurological Disorder Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Asia-Pacific 16-Year Perspective for Neurological Disorder Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 16-Year Perspective for Neurological Disorder Diagnostics by Product - Percentage Breakdown of Value Sales for Imaging Diagnostics and In-Vitro Diagnostics for the Years 2014, 2025 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 16-Year Perspective for Neurological Disorder Diagnostics by Disorder - Percentage Breakdown of Value Sales for Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder for the Years 2014, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 16-Year Perspective for Neurological Disorder Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Neurological Disorder Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 155: Australia Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Australia Historic Review for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Australia 16-Year Perspective for Neurological Disorder Diagnostics by Product - Percentage Breakdown of Value Sales for Imaging Diagnostics and In-Vitro Diagnostics for the Years 2014, 2025 & 2030
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Australia 16-Year Perspective for Neurological Disorder Diagnostics by Disorder - Percentage Breakdown of Value Sales for Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder for the Years 2014, 2025 & 2030
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Australia 16-Year Perspective for Neurological Disorder Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • INDIA
    • Neurological Disorder Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 164: India Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: India Historic Review for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: India 16-Year Perspective for Neurological Disorder Diagnostics by Product - Percentage Breakdown of Value Sales for Imaging Diagnostics and In-Vitro Diagnostics for the Years 2014, 2025 & 2030
    • TABLE 167: India Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: India 16-Year Perspective for Neurological Disorder Diagnostics by Disorder - Percentage Breakdown of Value Sales for Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder for the Years 2014, 2025 & 2030
    • TABLE 170: India Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: India 16-Year Perspective for Neurological Disorder Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 173: South Korea Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: South Korea Historic Review for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: South Korea 16-Year Perspective for Neurological Disorder Diagnostics by Product - Percentage Breakdown of Value Sales for Imaging Diagnostics and In-Vitro Diagnostics for the Years 2014, 2025 & 2030
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: South Korea 16-Year Perspective for Neurological Disorder Diagnostics by Disorder - Percentage Breakdown of Value Sales for Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder for the Years 2014, 2025 & 2030
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: South Korea 16-Year Perspective for Neurological Disorder Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Asia-Pacific Historic Review for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Rest of Asia-Pacific 16-Year Perspective for Neurological Disorder Diagnostics by Product - Percentage Breakdown of Value Sales for Imaging Diagnostics and In-Vitro Diagnostics for the Years 2014, 2025 & 2030
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 16-Year Perspective for Neurological Disorder Diagnostics by Disorder - Percentage Breakdown of Value Sales for Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder for the Years 2014, 2025 & 2030
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Neurological Disorder Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Neurological Disorder Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 191: Latin America Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 192: Latin America Historic Review for Neurological Disorder Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: Latin America 16-Year Perspective for Neurological Disorder Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: Latin America 16-Year Perspective for Neurological Disorder Diagnostics by Product - Percentage Breakdown of Value Sales for Imaging Diagnostics and In-Vitro Diagnostics for the Years 2014, 2025 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: Latin America 16-Year Perspective for Neurological Disorder Diagnostics by Disorder - Percentage Breakdown of Value Sales for Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder for the Years 2014, 2025 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: Latin America 16-Year Perspective for Neurological Disorder Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 203: Argentina Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Argentina Historic Review for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Argentina 16-Year Perspective for Neurological Disorder Diagnostics by Product - Percentage Breakdown of Value Sales for Imaging Diagnostics and In-Vitro Diagnostics for the Years 2014, 2025 & 2030
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Argentina 16-Year Perspective for Neurological Disorder Diagnostics by Disorder - Percentage Breakdown of Value Sales for Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder for the Years 2014, 2025 & 2030
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 211: Argentina 16-Year Perspective for Neurological Disorder Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 212: Brazil Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Brazil Historic Review for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 214: Brazil 16-Year Perspective for Neurological Disorder Diagnostics by Product - Percentage Breakdown of Value Sales for Imaging Diagnostics and In-Vitro Diagnostics for the Years 2014, 2025 & 2030
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 217: Brazil 16-Year Perspective for Neurological Disorder Diagnostics by Disorder - Percentage Breakdown of Value Sales for Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder for the Years 2014, 2025 & 2030
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 220: Brazil 16-Year Perspective for Neurological Disorder Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 221: Mexico Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Mexico Historic Review for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 223: Mexico 16-Year Perspective for Neurological Disorder Diagnostics by Product - Percentage Breakdown of Value Sales for Imaging Diagnostics and In-Vitro Diagnostics for the Years 2014, 2025 & 2030
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 226: Mexico 16-Year Perspective for Neurological Disorder Diagnostics by Disorder - Percentage Breakdown of Value Sales for Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder for the Years 2014, 2025 & 2030
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 229: Mexico 16-Year Perspective for Neurological Disorder Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Rest of Latin America Historic Review for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 232: Rest of Latin America 16-Year Perspective for Neurological Disorder Diagnostics by Product - Percentage Breakdown of Value Sales for Imaging Diagnostics and In-Vitro Diagnostics for the Years 2014, 2025 & 2030
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 235: Rest of Latin America 16-Year Perspective for Neurological Disorder Diagnostics by Disorder - Percentage Breakdown of Value Sales for Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder for the Years 2014, 2025 & 2030
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 238: Rest of Latin America 16-Year Perspective for Neurological Disorder Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Neurological Disorder Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 239: Middle East Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 240: Middle East Historic Review for Neurological Disorder Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 241: Middle East 16-Year Perspective for Neurological Disorder Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 244: Middle East 16-Year Perspective for Neurological Disorder Diagnostics by Product - Percentage Breakdown of Value Sales for Imaging Diagnostics and In-Vitro Diagnostics for the Years 2014, 2025 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 247: Middle East 16-Year Perspective for Neurological Disorder Diagnostics by Disorder - Percentage Breakdown of Value Sales for Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder for the Years 2014, 2025 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 250: Middle East 16-Year Perspective for Neurological Disorder Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 251: Iran Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Iran Historic Review for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 253: Iran 16-Year Perspective for Neurological Disorder Diagnostics by Product - Percentage Breakdown of Value Sales for Imaging Diagnostics and In-Vitro Diagnostics for the Years 2014, 2025 & 2030
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 256: Iran 16-Year Perspective for Neurological Disorder Diagnostics by Disorder - Percentage Breakdown of Value Sales for Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder for the Years 2014, 2025 & 2030
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 259: Iran 16-Year Perspective for Neurological Disorder Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 260: Israel Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Israel Historic Review for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 262: Israel 16-Year Perspective for Neurological Disorder Diagnostics by Product - Percentage Breakdown of Value Sales for Imaging Diagnostics and In-Vitro Diagnostics for the Years 2014, 2025 & 2030
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 265: Israel 16-Year Perspective for Neurological Disorder Diagnostics by Disorder - Percentage Breakdown of Value Sales for Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder for the Years 2014, 2025 & 2030
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 268: Israel 16-Year Perspective for Neurological Disorder Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Saudi Arabia Historic Review for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 271: Saudi Arabia 16-Year Perspective for Neurological Disorder Diagnostics by Product - Percentage Breakdown of Value Sales for Imaging Diagnostics and In-Vitro Diagnostics for the Years 2014, 2025 & 2030
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 274: Saudi Arabia 16-Year Perspective for Neurological Disorder Diagnostics by Disorder - Percentage Breakdown of Value Sales for Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder for the Years 2014, 2025 & 2030
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 277: Saudi Arabia 16-Year Perspective for Neurological Disorder Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 278: UAE Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: UAE Historic Review for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 280: UAE 16-Year Perspective for Neurological Disorder Diagnostics by Product - Percentage Breakdown of Value Sales for Imaging Diagnostics and In-Vitro Diagnostics for the Years 2014, 2025 & 2030
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 283: UAE 16-Year Perspective for Neurological Disorder Diagnostics by Disorder - Percentage Breakdown of Value Sales for Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder for the Years 2014, 2025 & 2030
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 286: UAE 16-Year Perspective for Neurological Disorder Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Rest of Middle East Historic Review for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 289: Rest of Middle East 16-Year Perspective for Neurological Disorder Diagnostics by Product - Percentage Breakdown of Value Sales for Imaging Diagnostics and In-Vitro Diagnostics for the Years 2014, 2025 & 2030
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 292: Rest of Middle East 16-Year Perspective for Neurological Disorder Diagnostics by Disorder - Percentage Breakdown of Value Sales for Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder for the Years 2014, 2025 & 2030
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 295: Rest of Middle East 16-Year Perspective for Neurological Disorder Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • AFRICA
    • Neurological Disorder Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 296: Africa Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Africa Historic Review for Neurological Disorder Diagnostics by Product - Imaging Diagnostics and In-Vitro Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 298: Africa 16-Year Perspective for Neurological Disorder Diagnostics by Product - Percentage Breakdown of Value Sales for Imaging Diagnostics and In-Vitro Diagnostics for the Years 2014, 2025 & 2030
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Neurological Disorder Diagnostics by Disorder - Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 301: Africa 16-Year Perspective for Neurological Disorder Diagnostics by Disorder - Percentage Breakdown of Value Sales for Genetic Neurological Disorder, Immunological Neurological Disorder, Paraneoplastic Syndrome Disorder and Paraproteinemic Neuropathies Disorder for the Years 2014, 2025 & 2030
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Neurological Disorder Diagnostics by End-Use - Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 304: Africa 16-Year Perspective for Neurological Disorder Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Specialty Clinics End-Use, Diagnostic Centers End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제